TheraCryf present an update on the Company including current status of R&D projects. Read More
June 13, 2024
Filter by:
Corporate Documents
Corporate Presentations
Scientific Posters & Presentations
Scientific Publications
Date
Title
Download
July 18, 2024
Voting on AGM Resolutions
June 21, 2024
Notice of AGM and Proxy Form
May 20, 2024
Capital Access Group Analyst Research
April 4, 2024
Voting on GM Resolutions
March 28, 2024
Notice of General Meeting
July 20, 2023
Voting on AGM Resolutions
June 20, 2023
Notice of AGM
July 21, 2022
Voting on AGM Resolutions
June 21, 2022
Notice of AGM
July 13, 2021
Voting on AGM resolutions
June 17, 2021
Notice of AGM
February 2, 2021
2021 Placing form of proxy
February 2, 2021
2021 Placing and Open Offer shareholder circular
October 15, 2015
AIM Admission Document
October 12, 2015
Articles of Association
Date
Title
Download
June 13, 2024
TheraCryf Research and Development Day
May 29, 2024
TheraCryf plc – Full Year Results
May 10, 2024
Corporate Presenation
April 25, 2024
Corporate Presentation
March 21, 2024
Corporate Presentation
December 31, 2023
Corporate Presentation
July 21, 2023
Investor Meet Company: Results and AGM 2023
March 23, 2023
Investor Meet Company & ProActive Investor Events Presentation
December 9, 2022
2022 Interim Results Presentation
October 12, 2022
Evgen Pharma Licensing and Clinical Programme Update
July 21, 2022
AGM Presentation – Harnessing the Power of Sulforaphane
January 4, 2022
Corporate Presentation – Harnessing the Power of Sulforaphane
Date
Title
Download
September 27, 2019
Final results of the STEM trial: SFX-01 in the Treatment and Evaluation of Metastatic breast cancer, presented at ESMO 2019
- Sacha Howell et al
March 28, 2019
Novel biomarkers for sulforaphane treated patients in ER+/HER- metastatic breast cancer, presented at ABPP 2019
- Daniel Conole et al
March 25, 2019
STEM Headline Results presentation, 25 March 2019
- Sacha Howell et al
December 4, 2018
STEM Trial: SFX-01 in the Treatment and Evaluation of Metastatic breast cancer, presented at the San Antonio Breast Cancer Symposium 2018
- Sally Ross et al
January 15, 2018
SFX-01 targets STAT3 signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours, presented at the UK Interdisciplinary Breast Cancer Symposium 2018
- Bruno Simoes et al
Date
Title
Download
October 18, 2023
The Sulforaphane Promise
- Helen Kuhlman
March 27, 2023
SFX-01 in the treatment of rhabdomyosarcoma: Preclinical results in cellular models
- Simona Camero et al
October 26, 2021
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human Glioblastoma
- Alessandro Colapietro et al
September 16, 2021
Effect of SFX-01 on proliferation of human glioblastoma cell lines
- Euphemia Leung et al
February 1, 2021
The novel atypical dopamine transport inhibitor CT-005404 has pro-motivational effects in neurochemical and inflammatory models of effort-based dysfunctions related to psychopathology
- Renee A. Rotolo et al
September 7, 2020
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
- Giacomo Salvadore et al
July 14, 2020
Can Activation of NRF2 Be a Strategy against COVID-19?
- Antonio Cuadrado et al
May 30, 2020
Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer
- Bruno Simoes et al
October 1, 2019
Final Results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC)
- Sacha Howell et al
February 5, 2019
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
- Antonio Cuadrado et al
October 28, 2014
Sulforaphane treatment of autism spectrum disorder (ASD)
- Kanwaljit Singh et al